Nanobiotix S.A. (NBTX) Stock Analysis & Investment Frameworks
Nanobiotix S.A. (NBTX) stock analysis on Invetso. Review Nanobiotix S.A.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Nanobiotix S.A. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: FR
Nanobiotix S.A. Key Financial Metrics
- Market Cap: $1.52B
- Revenue: $33.19M
- ROE: 89.71%
- ROIC: -40.79%
- Dividend Yield: N/A
About Nanobiotix S.A.
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.